HeyJaredCrystal Phend
- Indexed articles, last 90 days
- 5
- Latest publication
- Aug 27, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 17, 2026
Latest articles
Gabapentin Not Linked to Better Outcomes for Kidsâ Migraine (opens the original)
Read excerpt
For children hospitalized with migraine, gabapentin use wasn’t associated with less pain or fewer readmissions than with no gabapentin use, an observational study showed. “We should be cautious about assuming gabapentin is effective for pediatric migraine simply because it is commonly used,” said Maheshwor Kafle, MD, pediatric hospitalist at Phoenix Children’s Hospital in Phoenix. “Clinicians should prioritize therapies with stronger supporting evidence while also considering each patient’s indi
Inflammatory Hypothesis Proponents Undaunted by ZEUS Flop (opens the original)
Read excerpt
When topline results emerged from the ZEUS trial that investigational interleukin (IL)-6 agent ziltivekimab failed to reduce major cardiovascular events in patients with high-risk heart plus kidney disease, some saw it as a blow to the inflammatory hypothesis. Targeting IL-6 was supposed to reduce inflammation in these patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease, and high C-reactive protein. The monoclonal antibody appeared to hit that mark, cutting both
Thousands of US Kids Hospitalized for Vitamin Toxicity (opens the original)
Read excerpt
Thousands of children have been hospitalized after poisoning by vitamins and minerals in recent years, the majority ingested intentionally, a nationwide study showed. Over just 3 years, the federal Healthcare Cost and Utilization Project Kids’ Inpatient Database recorded vitamin and mineral toxicity as a cause of hospitalization for 1961 children. That represented just the supplements for which there was a toxicity-related International Classification of Diseases-10 code, said Marina Masciale, M
Oral PCSK9 Inhibitor Welcomed for Potential in Primary Care (opens the original)
Read excerpt
Approval of the first oral PCSK9 inhibitor could be a boon for some clinical scenarios, although questions remain about real-world impact on prescribing and adherence. FDA approval of the once-daily tablet, enlicitide, comes after years of speculation about whether an oral PCSK9 inhibitor would ever be developed to treat the tens of millions of patients eligible for them in the US. “It’s a nice addition to therapeutic armamentarium,” said Steven Nissen, MD, chief academic officer of the Heart, V
Grumblings Over CKM Guideline Not Warranted, Experts Say (opens the original)
Read excerpt
When new guidelines came out last month emphasizing cohesive management of cardiovascular, kidney, and metabolic health, reactions were mixed. “I was a little shocked at the pushback,” said Brian Rifkin, MD, a nephrologist at the Hattiesburg Clinic in Hattiesburg, Mississippi. “People called it a fake condition. They thought it was weak messaging, confusing staging. People were asking why we’re being asked to do more preventive cardiology, and is there going to be some kind of designation or cer
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.